Dongguan White Oak Pharma Breaks Ground on CDMO Facility Specializing in Nucleic Acid Therapeutics

Dec 06, 2024 16:08 CST Updated 16:08

Haichang Biotech

Innovative Formulation Developer

On December 5, 2024, during the highly anticipated 2024 Dongguan Global Investment Conference, the groundbreaking ceremony for the CDMO base of Dongguan White Oak Pharmaceuticals Co., Ltd. was grandly held.Chairman Zhao Xiaobin of Zhejiang Haichang Biomedical Technology Co., Ltd., General Manager Lin Shuang of Dongguan Songshan Lake Science City Development Group Co., Ltd., Vice President of Haichang Biotech and General Manager of Dongguan White Oak Pharmaceuticals Zhou Xiaoli, as well as leaders from construction units, supervision units, development units, and relevant departments, jointly witnessed this historic moment.

Dongguan White Oak Pharmaceuticals will expand Haichang Biotech's business in the CDMO direction, providing delivery solutions for the development of nucleic acid innovative drugs to meet the growing market demand.

Dongguan White Oak Pharmaceuticals, as a wholly-owned subsidiary of Haichang Biotech, undertakes the company's proprietary QTsome.^TMThe nucleic acid delivery technology platform offers open services externally, specializing in the research, development, and innovation of LNP liposome drugs and delivery systems. Services cover the entire lifecycle of drug development, including CDMO and regulatory registration, committed to providing global partners with professional, efficient, and high-quality solutions from preclinical to commercialization stages.

Dongguan White Oak CDMO Base, Focusing on Process Development and Quality Research for Nucleic Acid Innovative Drugs

This CDMO base construction project is located in Building 1 of Songshan Lake Science Wisdom City, Dongguan City, Guangdong Province. The planned renovation covers a construction area of 10,600 square meters and will include facilities for LNP liposome preparation, sterile formulation production, R&D laboratories, quality control laboratories, warehousing, clean utility systems, and offices. It is scheduled to be fully operational by 2026.

Looking ahead, Dongguan White Oak Pharmaceutical Co., Ltd. will continue to adhere to the development philosophy of "innovation-led, professionalism supreme, and efficient service." By leveraging the advantages of technical platform patents and industrialization, the professional capabilities in the development and transformation of nucleic acid innovative drugs, as well as resources for market registration and application in Europe, the United States, and other regions, the company aims to integrate the upstream and downstream industrial chains and promote the vigorous and rapid development of the entire industry and regional economy.

About Haichang Biotech

Haichang Biotech, located in China Medical Valley, Hangzhou, is a national-level specialized and innovative "little giant" enterprise that focuses on the technological innovation and development of biopharmaceuticals, integrating research, production, and sales of pharmaceuticals. The company adheres to its core values of "sharing, progress, truth-seeking, and pragmatism," with a focus on the development and industrialization of drug delivery systems. It specializes in the development of nucleic acid innovative drugs such as small nucleic acid drugs, mRNA vaccines, and complex injectables. Currently, injectable paclitaxel (albumin-bound) has been approved in 34 countries including China, the UK, and the EU, with ongoing registration in multiple Belt and Road countries; HC0301, a novel class 1 small nucleic acid drug, has received dual approval from the FDA and NMPA and is undergoing global multi-center Phase II clinical trials; the mRNA COVID-19 vaccine booster has been approved for clinical trials by the FDA, making it the first Chinese-produced mRNA vaccine product to receive U.S. clinical approval. The product pipeline covers areas such as anti-cancer, cancer immunotherapy, pain relief, and infectious disease prevention.